Chemotherapy’s gut damage turns out to have a surprising upside. By changing nutrient availability in the intestine, it ...

Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Chemotherapy reshapes gut bacteria in ways that send powerful signals throughout the body. These signals reprogram immune ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer ...

Jan 22 (Reuters) - Corcept Therapeutics said on Thursday a late-stage trial showed its experimental drug in combination with ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

Triple-Digit Gains. Corcept Therapeutics Inc. (NASDAQ:CORT) was one of the top performers last week. Corcept Therapeutics saw ...

A collaborative team of Chinese and U.S. scientists has identified a specific group of highly adaptable tumor cells that act as a ...

Corcept Therapeutics, sponsor of the ROSELLA trial, is currently evaluating relacorilant in other solid tumors, including platinum-sensitive ovarian cancer, endometrial cancer, cervical cancer, ...

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...

The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...